ZIVO Bioscience Announces Results of Study with its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Rhea-AI Summary

Zivo Bioscience (NASDAQ: ZIVO) announced disappointing results from a recent study on a novel immune-modulating product for coccidiosis treatment in broiler chickens, conducted by a third party. The trial faced a significantly higher than usual mortality rate due to an intense disease challenge, yielding results not reflective of commercial production conditions. Despite this setback, ZIVO remains confident in its product's potential and plans to conduct a new study, expected to conclude by mid-year. The company continues to prioritize coccidiosis treatment while exploring additional health benefits from its proprietary algal cultures.

Positive

• ZIVO's confidence in its novel product for treating coccidiosis remains intact despite the study setback.
• Plans to conduct a new study with results expected by mid-year demonstrate commitment to product validation.
• Potential for additional health benefits from proprietary algal cultures suggests future growth opportunities.

Negative

• Unexpectedly high mortality rate in the study (4-5 times higher than typical) raises concerns about product efficacy.
• Results of the recent trial were deemed questionable, potentially affecting investor confidence.

Due to an unexpectedly high mortality rate among tested chickens, ZIVO to conduct a new study with results expected by mid-year

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial in broiler chickens. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens produced questionable results due to a high disease burden among tested chickens.

The pathogen inoculation used in the study produced an unexpectedly strong and concentrated disease challenge that resulted in a mortality rate 4-5 times higher than a typical study, and not representative of conditions expected in commercial broiler production houses. Despite efforts to titrate the inoculum in advance to assure an appropriate study environment, the disease burden was elevated far beyond naturally occurring or target study conditions.

Based on numerous previously successful trials that more closely replicated disease levels observed in commercial production facilities, ZIVO remains confident that its novel product for broiler chickens represents a disruptive solution to coccidiosis, one of the most significant challenges facing the global poultry industry.

“Today’s news is a disappointing development for ZIVO Bioscience because we were expecting a favorable result from this latest test, as we have seen from numerous similar studies ZIVO has conducted and published. We plan to move forward quickly based on what we learned and have already begun the process to conduct a new study that should be completed by mid-year,” said John Payne, Chairman, Chief Executive Officer and President of ZIVO Bioscience.

"ZIVO remains focused on a biotech business strategy prioritizing its product candidate for the treatment of coccidiosis in chickens and continues work with the USDA for final approval. We believe this strategy will result in the best opportunity to optimize value through achieving sustainable revenue in the shortest timeframe possible. In addition to the poultry market, our extensive research indicates there are numerous additional health benefits or disease treatments to be derived from our proprietary algal culture for livestock, companion animals and humans. We intend to pursue those opportunities, as well,” added Mr. Payne.

About ZIVO Bioscience

ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.

Forward Looking Statements

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230210005373/en/

ZIVO Bioscience, Inc.

Keith Marchiando, Chief Financial Officer

(248) 452-9866 x130

kmarchiando@zivobioscience.com



LHA Investor Relations

Tirth T. Patel

(212) 201-6614

tpatel@lhai.com

Source: Zivo Bioscience, Inc.

FAQ

What were the results of the recent study by ZIVO Bioscience?

The study showed questionable results due to a high mortality rate among tested chickens, caused by a concentrated disease challenge.

When will ZIVO conduct the new study on coccidiosis treatment?

ZIVO plans to conduct a new study, with results expected by mid-year.

What impact did the study results have on ZIVO's stock?

The disappointing results may raise concerns among investors, potentially affecting ZIVO's stock performance.

How confident is ZIVO in its product despite the study setback?

ZIVO remains confident that its product for treating coccidiosis is a disruptive solution for the poultry industry.

What is ZIVO's focus moving forward after the study results?

ZIVO will continue to prioritize its coccidiosis product and explore additional health benefits from its algal cultures.